| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CC-885-CH2-PEG1-NH-CH3 targets cereblon (CRBN), a component of the E3 ubiquitin ligase complex. By binding to CRBN, the compound redirects the ubiquitin-proteasome system to degrade specific target proteins. The compound is a neoDegrader that induces targeted protein degradation. It is used in Antibody neoDegrader Conjugates (AnDCs) to specifically degrade target proteins in cancer cells.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, CC-885-CH2-PEG1-NH-CH3 binds to cereblon (CRBN) and induces targeted protein degradation. The compound's binding to CRBN can be assessed using surface plasmon resonance (SPR) or fluorescence polarization assays. The compound's ability to induce protein degradation can be evaluated in cell-free ubiquitination assays using purified E3 ligase components and target proteins.
|
| ln Vivo |
In cell-based assays, CC-885-CH2-PEG1-NH-CH3 induces targeted protein degradation through the E3 ubiquitin ligase pathway. The compound's effects are evaluated in cancer cell lines by measuring the degradation of specific target proteins by Western blotting. The compound can specifically degrade the target protein in cancer cells. It is used in the synthesis of Antibody neoDegrader Conjugates (AnDCs).
|
| Enzyme Assay |
The cell-free assay for CRBN binding involves measuring the binding of the compound to purified cereblon protein. This can be performed using surface plasmon resonance (SPR) to determine the binding affinity (KD). Fluorescence polarization or AlphaScreen assays can also be used. The compound's ability to induce protein degradation can be assessed using cell-free ubiquitination assays with purified E3 ligase components.
|
| Cell Assay |
Cell-based assays for CC-885-CH2-PEG1-NH-CH3 involve culturing cancer cell lines and treating them with the compound at concentrations ranging from 0.01 to 10 μM. Targeted protein degradation is assessed by measuring the levels of specific target proteins by Western blotting. Cell viability is assessed using MTT or CCK-8 assays. The compound's effects on the ubiquitin-proteasome system and downstream signaling pathways are evaluated.
|
| Animal Protocol |
In animal models, CC-885-CH2-PEG1-NH-CH3 has been evaluated as part of Antibody neoDegrader Conjugates (AnDCs) for targeted protein degradation. Typical studies involve administration of the AnDC to tumor-bearing mice via intravenous routes. Target protein degradation in tumors is assessed by Western blotting or immunohistochemistry. Tumor growth inhibition and survival are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CC-885-CH2-PEG1-NH-CH3 have not been extensively reported. As a small molecule with a molecular weight of 528.0 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically stored at low temperatures for research use. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
CC-885-CH2-PEG1-NH-CH3 is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent. As a neoDegrader that induces protein degradation, the compound may have effects on normal cells as well as cancer cells. Standard toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
CC-885-CH2-PEG1-NH-CH3 is a research-grade compound supplied for targeted protein degradation and AnDC research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a neoDegrader that can specifically degrade target proteins in cancer cells through the E3 ubiquitin ligase pathway. This product is intended for research use only.
|
| Molecular Formula |
C26H30CLN5O5
|
|---|---|
| Molecular Weight |
528.00
|
| Exact Mass |
527.193
|
| CAS # |
2722698-03-3
|
| Related CAS # |
CC-885-CH2-PEG1-NH-CH3 TFA
|
| PubChem CID |
157578821
|
| Appearance |
White to off-white solid powder
|
| LogP |
1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
37
|
| Complexity |
844
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N(C1=CC=C(CCOCCNC)C(Cl)=C1)C(NCC1C=CC2=C(C=1)CN(C1CCC(=O)NC1=O)C2=O)=O
|
| InChi Key |
CHFAZLBAAPOQTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H30ClN5O5/c1-28-9-11-37-10-8-17-3-4-19(13-21(17)27)30-26(36)29-14-16-2-5-20-18(12-16)15-32(25(20)35)22-6-7-23(33)31-24(22)34/h2-5,12-13,22,28H,6-11,14-15H2,1H3,(H2,29,30,36)(H,31,33,34)
|
| Chemical Name |
1-[3-chloro-4-[2-[2-(methylamino)ethoxy]ethyl]phenyl]-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~189.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8939 mL | 9.4697 mL | 18.9394 mL | |
| 5 mM | 0.3788 mL | 1.8939 mL | 3.7879 mL | |
| 10 mM | 0.1894 mL | 0.9470 mL | 1.8939 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
